Aidan Crawley, Amber Therapeutics CEO

UK medtech rais­es $100M for two-in-one uri­nary in­con­ti­nence treat­ment

Am­ber Ther­a­peu­tics com­plet­ed its $100 mil­lion Se­ries A raise to sup­port its im­plantable ther­a­py for mixed uri­nary in­con­ti­nence through a reg­is­tra­tional tri­al in 2026. …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.